166 related articles for article (PubMed ID: 23199954)
1. Introduction of human papillomavirus DNA screening in the world: 15 years of experience.
Castle PE; de Sanjosé S; Qiao YL; Belinson JL; Lazcano-Ponce E; Kinney W
Vaccine; 2012 Nov; 30 Suppl 5():F117-22. PubMed ID: 23199954
[TBL] [Abstract][Full Text] [Related]
2. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
3. New technologies and procedures for cervical cancer screening.
Cuzick J; Bergeron C; von Knebel Doeberitz M; Gravitt P; Jeronimo J; Lorincz AT; J L M Meijer C; Sankaranarayanan R; J F Snijders P; Szarewski A
Vaccine; 2012 Nov; 30 Suppl 5():F107-16. PubMed ID: 23199953
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the detection of HPV-16, 18, 31, 33, and 45 by type-specific DNA- and E6/E7 mRNA-based assays of HPV DNA positive women with abnormal Pap smears.
Salimović-Bešić I; Tomić-Čiča A; Smailji A; Hukić M
J Virol Methods; 2013 Dec; 194(1-2):222-8. PubMed ID: 24036071
[TBL] [Abstract][Full Text] [Related]
5. High performance of a new PCR-based urine assay for HPV-DNA detection and genotyping.
Tanzi E; Bianchi S; Fasolo MM; Frati ER; Mazza F; Martinelli M; Colzani D; Beretta R; Zappa A; Orlando G
J Med Virol; 2013 Jan; 85(1):91-8. PubMed ID: 23097252
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: a retrospective review of the Southern California Permanente Medical Group experience.
Lonky NM; Mahdavi A; Wolde-Tsadik G; Bajamundi K; Felix JC
J Low Genit Tract Dis; 2010 Jul; 14(3):200-5. PubMed ID: 20592555
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus testing for primary cervical cancer screening.
Grce M; Davies P
Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
[TBL] [Abstract][Full Text] [Related]
8. [The role of the cytological screening, HPV-test and the colposcopy for early detection of the precancerous lesions of the uterine cervix].
Ivanov S
Akush Ginekol (Sofiia); 2007; 46(9):45-9. PubMed ID: 18646309
[TBL] [Abstract][Full Text] [Related]
9. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
[TBL] [Abstract][Full Text] [Related]
10. The clinical performance of Invader technology and SurePath when detecting the presence of high-risk HPV cervical infection.
Harvey M; Stout S; Starkey CR; Hendren R; Holt S; Miller GC
J Clin Virol; 2009 Jul; 45 Suppl 1():S79-83. PubMed ID: 19651373
[TBL] [Abstract][Full Text] [Related]
11. A comparative review of laboratory-developed tests utilizing Invader HPV analyte-specific reagents for the detection of high-risk human papillomavirus.
Stillman MJ; Day SP; Schutzbank TE
J Clin Virol; 2009 Jul; 45 Suppl 1():S73-7. PubMed ID: 19651372
[TBL] [Abstract][Full Text] [Related]
12. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
13. HPV mRNA test in women with minor cervical lesions: experience of the University Hospital of North Norway.
Sorbye SW; Fismen S; Gutteberg TJ; Mortensen ES
J Virol Methods; 2010 Oct; 169(1):219-22. PubMed ID: 20638416
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of AMPLICOR HPV PCR and Linear Array assays on SurePath liquid-based Pap samples for the detection of high-risk HPV genotypes.
Chernesky M; Jang D; Portillo E; Smieja M; Chong S; Buracond S; Klingel M; El Sebai R; Kapala J; Patel J; Biers K; Harroun N; Doucette C; Sumner J
J Clin Virol; 2011 Mar; 50(3):201-4. PubMed ID: 21195020
[TBL] [Abstract][Full Text] [Related]
15. High-risk HPV DNA testing and HPV-16/18 genotyping: what is the clinical application?
Twiggs LB; Hopkins M
J Low Genit Tract Dis; 2011 Jul; 15(3):224-30. PubMed ID: 21716051
[TBL] [Abstract][Full Text] [Related]
16. Patient safety and the next generation of HPV DNA tests.
Simon K; Kondratovich MV; Hojvat S; Gutierrez A
Am J Clin Pathol; 2011 May; 135(5):798-9; author reply 799-803. PubMed ID: 21502437
[No Abstract] [Full Text] [Related]
17. Nucleic acid tests for the detection of alpha human papillomaviruses.
Poljak M; Cuzick J; Kocjan BJ; Iftner T; Dillner J; Arbyn M
Vaccine; 2012 Nov; 30 Suppl 5():F100-6. PubMed ID: 23199952
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the PapilloCheck® assay with the digene HC2 HPV DNA assay for the detection of 13 high-risk human papillomaviruses in cervical and anal scrapes.
Didelot MN; Boulle N; Damay A; Costes V; Segondy M
J Med Virol; 2011 Aug; 83(8):1377-82. PubMed ID: 21678441
[TBL] [Abstract][Full Text] [Related]
19. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology.
Thai H; Rangwala S; Gay T; Keating K; McLeod S; Nazarenko I; O'Neil D; Pfister D; Loeffert D
J Clin Virol; 2009 Jul; 45 Suppl 1():S93-7. PubMed ID: 19651375
[TBL] [Abstract][Full Text] [Related]
20. Impact of pap test compliance and cervical cancer screening intervals on human papillomavirus vaccine acceptance.
Ferris DG; Waller J; Dickinson A; McCracken C; Goebel A
J Low Genit Tract Dis; 2012 Jan; 16(1):39-44. PubMed ID: 22126831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
